Lexicon Pharmaceuticals Inc Cash Flow Conversion Efficiency
Lexicon Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Lexicon Pharmaceuticals Inc (LXRX) has a cash flow conversion efficiency ratio of -0.073x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.73 Million) by net assets ($202.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lexicon Pharmaceuticals Inc (1999–2025)
Cash flow conversion efficiency of Lexicon Pharmaceuticals Inc from 1999 to 2025. This chart illustrates how Lexicon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Lexicon Pharmaceuticals Inc for real-time trading data and today's change.
Lexicon Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Lexicon Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lexicon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lexicon Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see LXRX company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IRESS LTD
F:BRF
|
N/A |
|
Cromwell Property Group
AU:CMW
|
0.023x |
|
Hangzhou Pinming Software Co. Ltd. A
SHG:688109
|
0.025x |
|
Shanghai Amarsoft Information & Technolgy Co Ltd
SHE:300380
|
-0.055x |
|
Shandong Yanggu Huatai Chemical Co Ltd
SHE:300121
|
0.004x |
|
COMPASS PATHW SP.ADR
F:5Y6
|
-0.477x |
|
Hubei Radio and Television Information Network Co Ltd
SHE:000665
|
0.012x |
|
Indian Metals & Ferro Alloys Limited
NSE:IMFA
|
0.121x |
Annual Cash Flow Conversion Efficiency for Lexicon Pharmaceuticals Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Lexicon Pharmaceuticals Inc from 1999 to 2025. Review Lexicon Pharmaceuticals Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $107.54 Million | $-67.85 Million | -0.631x | +48.49% |
| 2024-12-31 | $145.95 Million | $-178.78 Million | -1.225x | +29.55% |
| 2023-12-31 | $93.11 Million | $-161.90 Million | -1.739x | -129.21% |
| 2022-12-31 | $117.12 Million | $-88.85 Million | -0.759x | +0.97% |
| 2021-12-31 | $113.59 Million | $-87.02 Million | -0.766x | +16.22% |
| 2020-12-31 | $156.37 Million | $-142.97 Million | -0.914x | -194.08% |
| 2019-12-31 | $117.10 Million | $113.81 Million | 0.972x | -82.73% |
| 2018-12-31 | $-26.41 Million | $-148.61 Million | 5.628x | +258.17% |
| 2017-12-31 | $52.10 Million | $-185.39 Million | -3.558x | -218.90% |
| 2016-12-31 | $157.40 Million | $-175.63 Million | -1.116x | -272.62% |
| 2015-12-31 | $285.85 Million | $184.78 Million | 0.646x | +342.78% |
| 2014-12-31 | $284.02 Million | $-75.62 Million | -0.266x | +50.26% |
| 2013-12-31 | $170.16 Million | $-91.08 Million | -0.535x | -51.11% |
| 2012-12-31 | $266.68 Million | $-94.46 Million | -0.354x | -19.86% |
| 2011-12-31 | $297.57 Million | $-87.94 Million | -0.296x | +11.37% |
| 2010-12-31 | $247.02 Million | $-82.37 Million | -0.333x | +38.76% |
| 2009-12-31 | $163.50 Million | $-89.02 Million | -0.544x | -11.53% |
| 2008-12-31 | $195.83 Million | $-95.60 Million | -0.488x | -88.23% |
| 2007-12-31 | $286.57 Million | $-74.32 Million | -0.259x | +61.03% |
| 2006-12-31 | $85.50 Million | $-56.91 Million | -0.666x | -343.62% |
| 2005-12-31 | $85.80 Million | $23.44 Million | 0.273x | +178.62% |
| 2004-12-31 | $121.59 Million | $-42.26 Million | -0.348x | -648.61% |
| 2003-12-31 | $166.22 Million | $-7.72 Million | -0.046x | +72.61% |
| 2002-12-31 | $169.90 Million | $-28.79 Million | -0.169x | -105.70% |
| 2001-12-31 | $218.37 Million | $-17.99 Million | -0.082x | -1039.20% |
| 2000-12-31 | $207.63 Million | $-1.50 Million | -0.007x | +99.38% |
| 1999-12-31 | $8.20 Million | $-9.60 Million | -1.171x | -- |
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercialize… Read more